Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Videos|November 8, 2013
Focusing on the Diabetes Patient
Jonathan G. Marquess, PharmD, CDE, explains why he decided to focus on caring for diabetes patients at his pharmacy.
Advertisement
Jonathan G. Marquess, PharmD, CDE, President and CEO of the Institute for Wellness and Education, Inc, explains why he decided to focus on caring for diabetes patients at his pharmacy. This interview was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
2
Intensive BP Control Cuts CV Risk Regardless of CKD Status
3
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
4
Inside the New Consensus Recommendations for Acute Stroke Care
5